FindTrial
Sign In

PF-08046054

DRUG2 trials

Sponsors

Seagen, a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Carcinoma, Non-Small-Cell LungEndometrial CancerEsophageal Squamous Cell CarcinomaGastric CancerHepatocellular CarcinomaNon-Small Cell Lung Cancer MetastaticNon-Small Cell Lung CarcinomaNon-small Cell Carcinoma

Phase 1

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RecruitingNCT05208762
Seagen, a wholly owned subsidiary of PfizerCarcinoma, Non-Small-Cell Lung, Endometrial Cancer, Esophageal Squamous Cell Carcinoma +5
Start: 2022-10-25End: 2029-01-04Target: 714Updated: 2026-07-22

Phase 3

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RecruitingNCT07144280
PfizerNon-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Start: 2025-09-29End: 2032-03-10Target: 680Updated: 2026-09-04

Related Papers

Reduction in circulating tumor DNA (ctDNA) in relation to radiographic response and tumor PD-L1 expression in a phase 1 study of PDL1V (PF-08046054) in patients with non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2026-05-28
152TiP PADL1NK-005: A randomized phase III trial of PDL1V (PF-08046054) monotherapy vs docetaxel in patients with previously treated PD-L1-positive non-small cell lung cancer
ESMO Open2026-03-17
Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial.
Journal of Clinical Oncology2025-05-28
Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.
Journal of Clinical Oncology2025-05-28
Abstract 322: Nonclinical characterization of the secondary mechanisms of action of PF-08046054 (PDL1V), a novel vedotin ADC directed to PD-L1 that selectively depletes tumor cells without depleting healthy immune cells
Cancer Research2025-04-21
Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).
Journal of Clinical Oncology2022-06-014 citations